Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital of Prato
Study design. Open-label, prospective, pilot study on patients with giant cell arteritis (GCA) resistant to corticosteroids (CS) .
Setting. Rheumatology department, Hospital of Prato, Prato, Italy. Treatment. All refractory GCA patients with or without involvement of aorta and its thoracic branches treated with intravenous TCZ at the dose of 8 mg/Kg/monthly or subcutaneous TCZ at the dose of 162 mg/weekly who achieved a stable remission over a 6-month period should receive reduced TCZ doses with the following schedules: intravenous TCZ tapering to 2 mg/Kg/monthly with drug withdrawal at month 4, and subcutaneous TCZ monthly reduction through the lengthening of injection intervals every 2, 3 , and 4 weeks, and with drug interruption at month 4.
Primary end-point. To investigate the maintenance of clinical remission after TCZ interruption over a 6-month follow-up period.
Secondary end-points. To assess the maintenance of clinical remission during the treatment, to evaluate the role of acute-phase reactants and PET in predicting the relapse and remission, and to assess the occurrence of adverse event (AEs).
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- All consecutive patients meeting the 1990 ACR classification criteria for GCA.
You may not be if
Corticosteroid treatment during the previous 6 months.
Uncontrolled diabetes.
Uncontrolled hypertension.
History of cancer within the past 5 years.
History of frequent infections in the past.
Positivity of screening procedures for latent tuberculosis infection.